Please assess the completion status of the following clinical trial:

Trial Title: Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Node positive Group (experimental group)~  * Primary melanoma \> 2 mm in depth~ * Metastasis must be \> 0.1 mm and detectable by IHC or hematoxylin and eosin (H\&E) to be considered node positive~ * Slides and block for primary and node must be archived in UH dermatopathology~* Node Negative Group (control group)~  * Primary melanoma \> 2 mm in depth~ * A negative sentinel lymph node must be negative by IHC and H\&E~    * No stage IV disease~   * No acral and mucosal histology~   * No history of prior invasive melanoma~   * Underwent primary excision and sentinel lymph node biopsy within 3 months of each other~   * Archived tissue available~ * Slides and block for primary tumor and node biopsy must be archived in University Hospitals Case Medical Center (UH) dermatopathology~Exclusion Criteria:~* Acral and mucosal histology~* Previous diagnosis of invasive melanoma~* previous chemotherapy or immunotherapy~* patients who are found to have stage IV disease during workup

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).